These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 11341346

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP.
    Cancer; 1996 Nov 15; 78(10):2146-52. PubMed ID: 8918407
    [Abstract] [Full Text] [Related]

  • 3. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
    Vogl FD, Frey M, Kreienberg R, Runnebaum IB.
    Br J Cancer; 2000 Nov 15; 83(10):1338-43. PubMed ID: 11044359
    [Abstract] [Full Text] [Related]

  • 4. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
    Gadducci A, Ferdeghini M, Buttitta F, Fanucchi A, Annicchiarico C, Prontera C, Bevilacqua G, Genazzani AR.
    Anticancer Res; 1996 Nov 15; 16(6B):3519-23. PubMed ID: 9042215
    [Abstract] [Full Text] [Related]

  • 5. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Leffers N, Lambeck AJ, de Graeff P, Bijlsma AY, Daemen T, van der Zee AG, Nijman HW.
    Gynecol Oncol; 2008 Sep 15; 110(3):365-73. PubMed ID: 18571704
    [Abstract] [Full Text] [Related]

  • 6. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
    Hornung R, Urs E, Serenella E, Edward W, Ursula S, Urs H, Daniel F.
    Cancer Lett; 2004 Mar 31; 206(1):97-106. PubMed ID: 15019165
    [Abstract] [Full Text] [Related]

  • 7. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer.
    Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Gagetti O, Bevilacqua G, Genazzani AR.
    Gynecol Oncol; 1999 Jan 31; 72(1):76-81. PubMed ID: 9889034
    [Abstract] [Full Text] [Related]

  • 8. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
    Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML.
    J Clin Oncol; 2006 Feb 10; 24(5):762-8. PubMed ID: 16391298
    [Abstract] [Full Text] [Related]

  • 9. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG, Dobberstein KU, Fittkau M, Bahn H, Holzhausen HJ, Gantchev L, Burkert W.
    Clin Cancer Res; 1995 Jul 10; 1(7):775-81. PubMed ID: 9816045
    [Abstract] [Full Text] [Related]

  • 10. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
    Qiu LL, Hua PY, Ye LL, Wang YC, Qiu T, Bao HZ, Wang L.
    Cancer Detect Prev; 2007 Jul 10; 31(1):45-9. PubMed ID: 17292563
    [Abstract] [Full Text] [Related]

  • 11. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
    Lenner P, Wiklund F, Emdin SO, Arnerlöv C, Eklund C, Hallmans G, Zentgraf H, Dillner J.
    Br J Cancer; 1999 Feb 10; 79(5-6):927-32. PubMed ID: 10070892
    [Abstract] [Full Text] [Related]

  • 12. [Serum anti-p53 antibodies in gastric cancer patients].
    Lawniczak M, Bielicki D, Sulzyc-Bielicka V, Marlicz K, Starzyńska T.
    Pol Merkur Lekarski; 2007 Sep 10; 23(135):192-5. PubMed ID: 18080693
    [Abstract] [Full Text] [Related]

  • 13. B7-H4 overexpression in ovarian tumors.
    Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR.
    Gynecol Oncol; 2006 Jan 10; 100(1):44-52. PubMed ID: 16256178
    [Abstract] [Full Text] [Related]

  • 14. [Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma--five years survival rate].
    Hofele C, Schwager-Schmitt M, Volkmann M.
    Laryngorhinootologie; 2002 May 10; 81(5):342-5. PubMed ID: 12001023
    [Abstract] [Full Text] [Related]

  • 15. Humoral p53 antibody response is a prognostic parameter in ovarian cancer.
    Mayerhofer K, Tempfer C, Kucera E, Hefler L, Zeisler H, Kainz C, Zeillinger R, Sliutz G.
    Anticancer Res; 1999 May 10; 19(1B):875-8. PubMed ID: 10216509
    [Abstract] [Full Text] [Related]

  • 16. Anti-p53 antibodies in serum of smokers and head and neck cancer patients.
    Wollenberg B, Jan NV, Pitzke P, Reiter W, Stieber P.
    Anticancer Res; 1997 May 10; 17(1A):413-8. PubMed ID: 9066686
    [Abstract] [Full Text] [Related]

  • 17. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
    Huober J, Sprenger H, Costa SD, Zentgraf H, Schmid H, Kaufmann M, Bastert G.
    Zentralbl Gynakol; 1996 May 10; 118(10):560-4. PubMed ID: 8999710
    [Abstract] [Full Text] [Related]

  • 18. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
    Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Genazzani AR.
    Anticancer Res; 1998 May 10; 18(5B):3763-5. PubMed ID: 9854491
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer.
    Pylväs M, Puistola U, Laatio L, Kauppila S, Karihtala P.
    Anticancer Res; 2011 Apr 10; 31(4):1411-5. PubMed ID: 21508394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.